Table 2.

Prognostic value of Mammaprint and Oncotype DX in matched samples

Multigene test	# of patients	# of death	5-year risk (95% CI)	Hazard ratio (95% CI)	C-index (95% CI)	Adjusted hazard ratio (95% CI)*
Mammaprint
Low risk	2908	52	3.4% (2.4%−4.7%)	1.00 (ref.)	0.614 (0.572–0.657)	1.00 (ref.)
High risk	2134	101	9.3% (7.4%−11.7%)	2.64 (1.89–3.69)		2.25 (1.56–3.25)
Oncotype DX
Low risk (RS 0–10)	1140	27	4.7% (3.0%−7.4%)	1.00 (ref.)	0.581 (0.530–0.631)	1.00 (ref.)
Intermediate risk (RS 11–25)	3068	74	5.2% (3.9%−6.8%)	0.98 (0.63–1.52)		1.04 (0.66–1.62)
High risk (RS >25)	834	52	12.4% (9.1%−16.8%)	2.45 (1.54–3.91)		1.81 (1.05–3.09)
Oncotype DX + node status †
Low risk	3503	76	4.7% (3.6%−6.2%)	1.00 (ref.)	0.608 (0.563–0.653)	1.00 (ref.)
High risk	1539	77	9.9% (7.6%−12.7%)	2.19 (1.59–3.00)		1.63 (1.07–2.48)

Abbreviation: CI, confidence intervals; RS, recurrence score.

^*Adjusted for age, race, Charlson Comorbidity Index, nodal status, tumor size, progesterone receptor status, tumor grade and lymphovascular invasion

^†New Oncotype DX category: low risk if RS <26 and node negative or RS <11 and node positive; high risk if RS >25 and node negative or RS >10 and node positive